Last reviewed · How we verify

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml — Competitive Intelligence Brief

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml (Levobupivacaine 0.1% + Sufentanil 0.2µg/ml) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid combination. Area: Anesthesia / Pain Management.

phase 3 Local anesthetic + opioid combination Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil) Anesthesia / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml (Levobupivacaine 0.1% + Sufentanil 0.2µg/ml) — Dr Madeleine Wilwerth. Levobupivacaine blocks sodium channels to provide local anesthesia, while sufentanil activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levobupivacaine 0.1% + Sufentanil 0.2µg/ml TARGET Levobupivacaine 0.1% + Sufentanil 0.2µg/ml Dr Madeleine Wilwerth phase 3 Local anesthetic + opioid combination Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)
Hyperbaric bupivacaine+Sufentanil Hyperbaric bupivacaine+Sufentanil Fundación Pública Andaluza Progreso y Salud marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (sufentanil)
Hyperbaric bupivacaine+Morphine Hyperbaric bupivacaine+Morphine Fundación Pública Andaluza Progreso y Salud marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
Levobupivacaine plus sufentanil epidural infusion Levobupivacaine plus sufentanil epidural infusion University of Genova marketed Local anesthetic + opioid combination Voltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
Bupivacaine + Sufentanil epidural Bupivacaine + Sufentanil epidural Charles University, Czech Republic marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
Bupivacaine heavy and Morphine Bupivacaine heavy and Morphine Post Graduate Institute of Medical Education and Research, Chandigarh marketed Local anesthetic + opioid combination Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (morphine)
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml Levobupivacaine 0.07% + Sufentanil 0.3µg/ml Dr Madeleine Wilwerth phase 3 Local anesthetic + opioid combination Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid combination class)

  1. Dr Madeleine Wilwerth · 2 drugs in this class
  2. Fundación Pública Andaluza Progreso y Salud · 2 drugs in this class
  3. Charles University, Czech Republic · 1 drug in this class
  4. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
  5. University of Genova · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levobupivacaine 0.1% + Sufentanil 0.2µg/ml — Competitive Intelligence Brief. https://druglandscape.com/ci/levobupivacaine-0-1-sufentanil-0-2-g-ml. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: